Department of Critical Care Medicine, Manipal Hospital, Bengaluru, India.
Department of Anaesthesia, Teerthanker Mahaveer Medical College, Teerthanker Mahaveer University, Moradabad, Uttar Pradesh, India.
Pan Afr Med J. 2022 Jan 26;41:74. doi: 10.11604/pamj.2022.41.74.28865. eCollection 2022.
to evaluate the effects of intravenous (IV) dexmedetomidine as a pre-medication on clinical profile of bupivacaine spinal anaesthesia in lower abdominal surgeries.
this prospective randomized double blind study was done on 60 patients with ASA grade I/II undergoing lower abdominal surgeries under bupivacaine spinal anaesthesia. They were allocated to group-1 and group-2. Group-1 (control group) received normal saline and group-2 (study group) received IV dexmedetomidine 1 µg/kg over 10 min as premedication. Five minutes after premedication, subarachnoid block (SAB) was given with 3 ml of 0.5% hyperbaric bupivacaine following which sensory and motor blockade, hemodynamic changes, sedation, and complications of the surgery were recorded and this data was analyzed statistically using χ test, corrected χ test, Fisher´s exact test, and test of proportion (Z-test).
the results of the present study showed that in group-2 there was significant decrease in the onset of sensory block, higher level of sensory blockade achieved, less time required to attain highest level of anaesthesia, prolonged time required for 2 dermatomal regression, prolonged duration of sensory blockade, prolonged duration of analgesia, decrease in onset of motor blockade, no significant increase in duration of motor blockade, there was overall hemodynamic stability except for few cases of bradycardia responding to atropine and hypotension responding to mephentramine, adequate and acceptable intraoperative sedation, and significantly less incidence of shivering in perioperative period.
IV infusion of dexmedetomidine 1 µg/kg body weight prior to SAB can be recommended to achieve better sensory blockade and adequate hemodynamic stability and sedation.
评估静脉注射(IV)右美托咪定作为术前用药对下腹手术布比卡因脊髓麻醉临床特征的影响。
本前瞻性随机双盲研究纳入了 60 名 ASA 分级 I/II 级接受布比卡因脊髓麻醉下下腹手术的患者。他们被分为组 1 和组 2。组 1(对照组)接受生理盐水,组 2(研究组)接受 IV 右美托咪定 1μg/kg 静脉输注 10 分钟作为术前用药。给药后 5 分钟,行蛛网膜下腔阻滞(SAB),给予 3ml 0.5%超比重布比卡因,然后记录感觉和运动阻滞、血流动力学变化、镇静以及手术并发症,并使用 χ 检验、校正 χ 检验、Fisher 确切检验和比例检验(Z 检验)对数据进行统计学分析。
本研究结果显示,组 2 感觉阻滞的起始时间明显缩短,达到更高的感觉阻滞水平,达到最高麻醉水平所需的时间更少,2 个皮节感觉阻滞消退所需的时间延长,感觉阻滞持续时间延长,镇痛持续时间延长,运动阻滞起始时间延迟,运动阻滞持续时间无明显延长,除少数心动过缓病例对阿托品有反应和低血压病例对麻黄碱有反应外,总体血流动力学稳定,术中镇静充分且可接受,围手术期寒战发生率明显降低。
SAB 前静脉输注右美托咪定 1μg/kg 体重可推荐用于实现更好的感觉阻滞和足够的血流动力学稳定性和镇静。